Stage‐dependent management paradigms for MEN1 ‐related Zollinger–Ellison syndrome: A vignette‐based study by the ENETS MEN1 Task Force across 57 expert centers
Journal of Neuroendocrinology · 2026-11 · 38 (11)
DOI: 10.1111/jne.70304 ↗Abstract
Abstract Management of Zollinger–Ellison syndrome (ZES) in patients with multiple endocrine neoplasia type 1 (MEN1) remains controversial, particularly in non‐metastatic disease where the role of surgery is debated. In contrast, treatment of metastatic disease is guided by established systemic approaches. We aimed to evaluate stage‐dependent clinical decision‐making in MEN1‐related ZES using standardized clinical vignettes across ENETS Centers of Excellence (CoEs). A questionnaire‐based study using two clinical vignettes was conducted by the ENETS MEN1 Task Force across all 68 ENETS CoEs, with a predefined participation target of 70%. Additional non‐ENETS expert centers were also invited. Dedicated multidisciplinary teams provided institutional consensus responses. Scenarios included non‐metastatic disease, locally metastatic disease, and distant metastatic disease. Centers were stratified by volume using a cutoff of 30 MEN1 patients in active care. Data were analyzed descriptively, comparing management strategies between low‐ and high‐volume centers. Fifty‐seven centers participated (52 of 68 ENETS CoEs [76.5%] and 5 additional non‐ENETS expert centers). All 57 centers completed the questionnaire in full. All cases received symptomatic therapy with proton pump inhibitors. In non‐metastatic disease, management was heterogeneous, with 56.1% recommending surgery. Centre volume strongly influenced decisions (73.1% vs. 41.9% surgery in low‐ vs. high‐volume centers, p = .018). Preferred surgical approaches included duodenotomy with regional lymphadenectomy (43.9%) and the Thompson procedure (left pancreatectomy, duodenal exploration with excision of tumors and node dissection, enucleation of pancreatic head lesions; 26.3%). In locally metastatic disease, surgical management increased to 78.9%, with a shift toward more extensive procedures including pancreaticoduodenectomy (35.1%). In distant metastatic disease, somatostatin analogues were the systemic therapy of choice (50.9%), followed by curative‐intent surgery with pancreaticoduodenectomy or duodenotomy with regional lymphadenectomy combined with liver resection or thermal ablation of liver lesions (35.1%), while no other systemic treatments were selected by any center. A liver biopsy was recommended by 43.9% of centers. Management of MEN1‐related ZES demonstrates stage‐dependent convergence. In early disease, decision‐making—particularly regarding surgical versus medical management—is highly variable and influenced by center experience, whereas advanced disease shows more consistent, guideline‐aligned treatment patterns. The high participation rate across ENETS CoEs suggests that these findings are likely to be relevant to expert neuroendocrine tumor practice.
EUVIMED